Skip to main content
Clinical Trials/ACTRN12615001301550
ACTRN12615001301550Completed未知

In 20 overweight post-menopausal women, the effect of boysenberry drinks are compared with inulin (positive control) and maltodextrin (placebo) on appetite and food intake.

Plant and Food Research0 sites20 target enrollmentStarted: November 30, 2015Last updated:

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
50 Years to 70 Years (—)
Sex
Female

Inclusion Criteria

  • Aged 50-70 years
  • BMI between 25 and 35 kg/m2
  • Postmenopausal defined either by age greater than 60 years; or no menopausal cycle in the past 12 months.
  • Generally healthy, as ascertained by self-report

Exclusion Criteria

  • Any reported medical conditions or medications known to affect appetite -related parameters, including depression
  • Low iron status, hence unsuitable for cannulation studies
  • Participation in an active diet program and/or loss/gain of >10% body weight within the last 6 months
  • Smoker or ex-smoker who quit within the last 6 months
  • Body Mass Index greater than or equal to 35 kg/m2, or less than or equal to 25 kg/m2.
  • Reported major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • Reported history of active uncontrolled gastrointestinal disorders or diseases including: inflammatory bowel disease (IBD), ulcerative colitis), Crohn's disease or indeterminate colitis; irritable bowel syndrome (IBS) (persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhoea of unknown aetiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated); chronic and recurring constipation of >5 days.
  • Reported use of any of the following drugs within the last 6 months: systemic antibiotics (intravenous, intramuscular, or oral); corticosteroids (oral, intravenous, intramuscular, nasal or inhaled); cytokines; methotrexate or immunosuppressive cytotoxic agents;
  • Large doses of commercial probiotics consumed (greater than or equal to108 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply.
  • Acute disease at the time of enrolment (defer sampling until –participant recovers), included clinically raised blood pressure of >160/100 mm/Hg. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Chronic, clinically significant (unresolved, requiring on-going medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by reported medical history
  • Reported history of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
  • Reported positive test for HIV, HBV or HCV.
  • Hypersensitivities or allergies to any foods or ingredients included in the study
  • Dislike and/or unwilling to consume items listed as study foods
  • Unwilling/unable to comply with study protocol
  • Participating in another clinical intervention trial

Investigators

Sponsor
Plant and Food Research

Similar Trials